Clinical Trials Logo

Sialorrhea clinical trials

View clinical trials related to Sialorrhea.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03704168 Withdrawn - Neurologic Disorder Clinical Trials

Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders

SECAMS
Start date: May 1, 2019
Phase: N/A
Study type: Interventional

To evaluate safety of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations. Secondary Objective: To evaluate efficacy of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations. Duration: Estimation for Recruitment: 12 months Estimation for Procedure/Trial: 1 visit with an overnight observation Estimation for Subject Follow Up: 7 days, 14 days, 28 days, 90 days, and 180 days, post ablation, with ultrasound of the bilateral submandibular glands at 28 days and 180 days post ablation Total Expected Duration for Clinical Trial: 2 years

NCT ID: NCT01565395 Withdrawn - Parkinson Disease Clinical Trials

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

Xeomin
Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.